Elucidating the precise role of FcγRIV in the underlying pathomechanism of murine EBA may shed light on potential therapeutic targets and rationalize evaluating the utility of agents blocking FcγRIV or FcγR signaling pathways. Here, FCGR2A is linked to acquired epidermolysis bullosa.